| ČULEN, Martin, Marek BORSKÝ, Veronika NÉMETHOVÁ, Filip RÁZGA, Jiri SMEJKAL, Tomáš JURČEK, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ, Barbora WEINBERGEROVÁ, Lukáš SEMERÁD, Irina SADOVNIK, Gregor EISENWORT, Harald HERRMANN, Peter VALENT, Jiří MAYER and Zdeněk RÁČIL. Quantitative assessment of the CD26+leukemic stem cell compartment in chronic myeloid leukemia: Patient-subgroups, prognostic impact, and technical aspects. Oncotarget. Albany: Impact Journals, 2016, vol. 7, No 22, p. 33016-33024. ISSN 1949-2553. Available from: https://dx.doi.org/10.18632/oncotarget.9108. |
Other formats:
BibTeX
LaTeX
RIS
@article{1349286,
author = {Čulen, Martin and Borský, Marek and Némethová, Veronika and Rázga, Filip and Smejkal, Jiri and Jurček, Tomáš and Dvořáková, Dana and Žáčková, Daniela and Weinbergerová, Barbora and Semerád, Lukáš and Sadovnik, Irina and Eisenwort, Gregor and Herrmann, Harald and Valent, Peter and Mayer, Jiří and Ráčil, Zdeněk},
article_location = {Albany},
article_number = {22},
doi = {http://dx.doi.org/10.18632/oncotarget.9108},
keywords = {CML; LSC; DPPIV/CD26; FISH; FACS},
language = {eng},
issn = {1949-2553},
journal = {Oncotarget},
title = {Quantitative assessment of the CD26+leukemic stem cell compartment in chronic myeloid leukemia: Patient-subgroups, prognostic impact, and technical aspects},
volume = {7},
year = {2016}
}
TY - JOUR
ID - 1349286
AU - Čulen, Martin - Borský, Marek - Némethová, Veronika - Rázga, Filip - Smejkal, Jiri - Jurček, Tomáš - Dvořáková, Dana - Žáčková, Daniela - Weinbergerová, Barbora - Semerád, Lukáš - Sadovnik, Irina - Eisenwort, Gregor - Herrmann, Harald - Valent, Peter - Mayer, Jiří - Ráčil, Zdeněk
PY - 2016
TI - Quantitative assessment of the CD26+leukemic stem cell compartment in chronic myeloid leukemia: Patient-subgroups, prognostic impact, and technical aspects
JF - Oncotarget
VL - 7
IS - 22
SP - 33016-33024
EP - 33016-33024
PB - Impact Journals
SN - 19492553
KW - CML
KW - LSC
KW - DPPIV/CD26
KW - FISH
KW - FACS
N2 - Little is known about the function and phenotype of leukemic stem cells (LSCs) in chronic myeloid leukemia (CML) or about specific markers that discriminate LSCs from normal hematopoietic stem cells (HSCs). CD26 has recently been described as a specific marker of CML LSCs. In the current study, we investigated this marker in a cohort of 31 unselected CML patients. BCR/ABL1 positivity was analyzed in highly enriched stem cell fractions using fluorescence in situ hybridization (FISH) and reverse transcription PCR (RT-PCR). The proportion of CD26(+) LSCs and CD26(-)HSCs varied considerably among the patients analyzed, and the percentage of CD26(+) cells correlated with leukocyte count. The CD26 expression robustly discriminated LSCs from HSCs. This required a strict gating of the stem cell compartment. Thus, in patients with very low LSC or HSC numbers, only the highly sensitive RT-PCR method discriminated between clonal and non-clonal cells, while a robust FISH analysis required larger numbers of cells in both compartments. Finally, our data show that the numbers of CD26(+) CML LSCs correlate with responses to treatment with BCR-ABL1 inhibitors.
ER -
ČULEN, Martin, Marek BORSKÝ, Veronika NÉMETHOVÁ, Filip RÁZGA, Jiri SMEJKAL, Tomáš JURČEK, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ, Barbora WEINBERGEROVÁ, Lukáš SEMERÁD, Irina SADOVNIK, Gregor EISENWORT, Harald HERRMANN, Peter VALENT, Jiří MAYER and Zdeněk RÁČIL. Quantitative assessment of the CD26+leukemic stem cell compartment in chronic myeloid leukemia: Patient-subgroups, prognostic impact, and technical aspects. \textit{Oncotarget}. Albany: Impact Journals, 2016, vol.~7, No~22, p.~33016-33024. ISSN~1949-2553. Available from: https://dx.doi.org/10.18632/oncotarget.9108.
|
